StartupsAI ventures
Flagship commits £100 million to create AI companies in London
“The firm behind Moderna plans to recruit about 50 people for its first dedicated company-creation unit outside the US and seek further funding through partnerships.”
How this story was made
This story was written with AI assistance from Flagship Pioneering’s own announcement. Its figures and quotations were checked against their sources, and Digitalage Desk reviewed and approved it before publication. It is published under the name of Peter Michaels, Editor.
Flagship Pioneering, the firm behind Moderna, has committed an initial £100 million to establish a London operation that will develop new companies built around artificial intelligence.
The operation, Flagship Origination Lab, U.K., will form part of Flagship Labs, its company-creation arm. In its November 16 announcement, Flagship described it as its first dedicated unit of that kind outside the United States, with plans to work across human and planetary health and other scientific and technological fields.
Flagship expects to recruit and train an initial team of approximately 50 scientist-entrepreneurs and operators. Founder and CEO Noubar Afeyan also said it anticipates attracting an additional £500 million through partnerships.
That additional funding remains to be secured, according to Flagship’s responses to European Biotechnology. The company told the publication it was discussing potential partnerships and had received strong interest.
Creating companies from research
Flagship develops scientific ideas internally and builds companies around promising work. The London team is intended to follow that approach, drawing on the firm’s experience and resources to develop ventures of its own.
The company told European Biotechnology that it expects to collaborate with British universities and research institutions, while originating scientific concepts mainly through its own process.
Flagship calls the proposed ventures “AI-native.” It told the publication that AI increasingly informs how it asks scientific questions, generates hypotheses, designs experiments and develops products.
Funding the operation and its first ventures
The initial £100 million will cover establishing the operation, recruiting staff, developing scientific capabilities and investing in its first companies, a Flagship spokesperson told European Biotechnology. The company did not disclose a split between operating costs and venture investments.
Flagship already has a British presence. A November 2023 UK government announcement confirmed its London base and a memorandum of understanding covering cooperation on clinical trials, potential manufacturing locations and genomics. The new operation adds dedicated company-creation capabilities to that existing relationship.
Primary sourceFlagship Pioneering: “Flagship Pioneering launches Flagship Origination Lab in London to create AI-native platform companies in the U.K.”The first ventures and their founding teams were not identified in the European Biotechnology report. Flagship told the publication that it had not committed to a timetable for launching its first companies and intended to develop and test ideas from the outset. Its immediate priorities are assembling the team, establishing scientific capabilities and advancing potential ventures toward formation.
End of story


